Apoptosis regulator B-cell lymphoma 2 (BCL2)

Apoptosis regulator B-cell lymphoma 2 (BCL-2) is a pivotal anti-apoptotic protein that governs the intrinsic mitochondrial pathway of programmed cell death [UniProt, 2017]. It primarily resides on the outer mitochondrial membrane, where it inhibits apoptosis by sequestering pro-apoptotic proteins like BAX and BAK, preventing the release of cytochrome c and subsequent caspase activation [NIH, 2017]. BCL-2 was the first mammalian gene identified to promote cell survival rather than proliferation, and its overexpression is a common driver in various cancers, notably chronic lymphocytic leukemia (CLL) and follicular lymphoma [Wikipedia, 2024]. In these malignancies, high BCL-2 levels allow tumor cells to evade death signals and develop resistance to conventional chemotherapy [Guide to Pharmacology, 2023]. The therapeutic landscape for BCL-2-driven diseases has been transformed by BH3 mimetics like venetoclax, which specifically inhibit BCL-2 to restore the apoptotic process [ASH Publications, 2020]. Beyond its role in oncology, BCL-2 is involved in regulating autophagy, calcium homeostasis, and inflammation, with dysregulation linked to autoimmune and neurodegenerative disorders [ResearchGate, 2021]. Clinical challenges associated with BCL-2 inhibition include the risk of tumor lysis syndrome and the emergence of resistance through BCL2 mutations or upregulation of alternative survival proteins like MCL-1 [NIH, 2024].

Other names

B-cell CLL/lymphoma 2Bcl-2PPP1R50BCL2 apoptosis regulator

BCL-2 inhibitors, specifically BH3 mimetics, bind to the hydrophobic BH3-binding groove of the BCL-2 protein. This action displaces pro-apoptotic proteins (such as BIM, BAX, or BAK) that were sequestered by BCL-2, thereby allowing these proteins to induce mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and subsequent caspase-mediated apoptosis [ASH Publications, 2020; NIH, 2017].